Open AccessAdjuvant Olaparib Improves Outcomes in High-Risk, HER2-Negative Early Breast Cancer Patients With Germline BRCA1 and BRCA2 Mutations
Author(s) -
Abdelsamia
Publication year - 2021
Publication title -
journal of clinical outcomes management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 19
eISSN - 1938-1336
pISSN - 1079-6533
DOI - 10.12788/jcom.0074
Subject(s) - medicine , olaparib , germline , oncology , adjuvant , breast cancer , germline mutation , brca mutation , her2 negative , cancer , gynecology , mutation , genetics , metastatic breast cancer , gene , poly adp ribose polymerase , polymerase , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom